Navigation Links
Cord Blood America Secured $7.5 Million Investment For Series A Preferred Stock

SANTA MONICA, Calif., July 7 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies ( focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has entered into a definitive agreement with a health care fund under which Cord Blood America has secured a $7.5 million investment capital commitment, which may be drawn down through the sale of Series A Preferred Stock once a registration statement is filed and declared effective under the Securities Act of 1933.

Proceeds of the investment are anticipated to be used to fund new stem cell initiatives, potential acquisitions, and working capital needs. Matthew Schissler, founder and CEO, said the proceeds, once available and when coupled with internally generated revenues, should be sufficient to fund operations in the foreseeable future.

The Company may drawdown funds from the fund, based on terms and market conditions, through the issuance of Series A Preferred Stock and five-year Warrants exercisable for shares of common stock.

"This long term equity financing will allow for the company to grow and expand in ways we have not seen before, without the constant pressure of discounted debt financing. As stated throughout 2009, our three pillars of planned business success include organic growth, acquisitions and debt reduction. This financing will provide us the capital needed for the first two, without adding debt to the balance sheet."

"To have secured this financing in these difficult economic times is a major signal and endorsement of our business strategies and our management team," Mr. Schissler said.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at For investor information, visit

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

        Paul Knopick
        E & E Communications

SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
2. Cord Blood America Continues International Expansion
3. Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
4. Researchers solve bloodcurdling mystery
5. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
6. Cord Blood America Says Debt Reduced $4.194 Million in 2009
7. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
8. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
9. SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal
10. Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory
11. Cord Blood America Supports Effort in Congress to Inform on Value of Umbilical Cord Blood Stem Cell Storage
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP ... states to develop and pitch their BIG ideas to improve health and wellness in ... for votes to win the title of SAP's Teen Innovator, an all-expenses paid trip ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):